{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:28Z","timestamp":1786983808677,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier","isbn-type":[{"value":"9780323899390","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.ircmb.2021.07.002","type":"book-chapter","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:29:22Z","timestamp":1635420562000},"page":"97-116","source":"Crossref","is-referenced-by-count":8,"title":["Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies"],"prefix":"10.1016","member":"78","reference":[{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.002_bb0010","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/modpathol.2015.117","article-title":"Renal extramedullary hematopoiesis: interstitial and glomerular pathology","volume":"28","author":"Alexander","year":"2015","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.002_bb0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.24269","article-title":"Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients","volume":"91","author":"Andriani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0020","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/CMAR.S161746","article-title":"Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review","volume":"10","author":"Bao","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.07.002_bb0025","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"issue":"20","key":"10.1016\/bs.ircmb.2021.07.002_bb0030","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/bs.ircmb.2021.07.002_bb0035","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.002_bb0040","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4065\/70.12.1161","article-title":"Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion","volume":"70","author":"Bartlett","year":"1995","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.22233","article-title":"Long-term outcome of pomalidomide therapy in myelofibrosis","volume":"87","author":"Begna","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/bs.ircmb.2021.07.002_bb0055","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2012-07-446849","article-title":"Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly","volume":"120","author":"Benjamini","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/bs.ircmb.2021.07.002_bb0060","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0065","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000441-198805000-00011","article-title":"Remission of chronic idiopathic myelofibrosis to busulfan treatment","volume":"295","author":"Chang","year":"1988","journal-title":"Am. J. Med. Sci."},{"issue":"17","key":"10.1016\/bs.ircmb.2021.07.002_bb0070","doi-asserted-by":"crossref","first-page":"7799","DOI":"10.1073\/pnas.1003586107","article-title":"Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells","volume":"107","author":"Chou","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0020075","article-title":"Circulation and chemotaxis of fetal hematopoietic stem cells","volume":"2","author":"Christensen","year":"2004","journal-title":"PLoS Biol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0080","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00415-009-5020-y","article-title":"Dural localization of extramedullary hematopoiesis. Report of a case","volume":"256","author":"Debard","year":"2009","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0950-3536(97)80005-4","article-title":"Stem cell kinetics","volume":"10","author":"Eaves","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.002_bb0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.002_bb0100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3346\/jkms.2007.22.6.1090","article-title":"Chronic idiopathic myelofibrosis presenting as cauda equina compression due to extramedullary hematopoiesis: a case report","volume":"22","author":"Goh","year":"2007","journal-title":"J. Korean Med. Sci."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.002_bb0105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bcmd.2013.08.004","article-title":"Embryonic hematopoiesis","volume":"51","author":"Golub","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0110","first-page":"549","article-title":"Profile of pomalidomide and its potential in the treatment of myelofibrosis","volume":"11","author":"Gowin","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.07.002_bb0115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.07.002_bb0120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/modpathol.3880135","article-title":"Myocardial extramedullary hematopoiesis: a clinicopathologic study","volume":"13","author":"Hill","year":"2000","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0002-9343(84)91023-4","article-title":"Cutaneous extramedullary hematopoiesis following splenectomy for idiopathic myelofibrosis","volume":"76","author":"Hocking","year":"1984","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s13730-017-0274-1","article-title":"A case of perirenal extramedullary hematopoiesis in a patient with primary myelofibrosis","volume":"6","author":"Imai","year":"2017","journal-title":"CEN Case Rep."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.002_bb0135","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/JBM.S7224","article-title":"Homeostatic and pathogenic extramedullary hematopoiesis","volume":"1","author":"Kim","year":"2010","journal-title":"J. Blood Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.07.002_bb0145","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4065\/78.10.1223","article-title":"Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment","volume":"78","author":"Koch","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0150","series-title":"Proc (Bayl Univ Med Cent)","first-page":"69","article-title":"Extramedullary hematopoiesis masquerading as a cranial (clivus) tumor","volume":"vol. 33","author":"Krause","year":"2020"},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0155","first-page":"e135","article-title":"JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug","volume":"vol. 98","author":"Kuriakose","year":"2013"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.002_bb0160","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/1097-0142(19910915)68:6<1251::AID-CNCR2820680612>3.0.CO;2-1","article-title":"Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia","volume":"68","author":"Leinweber","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0002-9343(91)90513-W","article-title":"Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature","volume":"90","author":"Liot\u00e9","year":"1991","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.002_bb0170","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.002_bb0175","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1242\/dev.040998","article-title":"Embryonic origin of the adult hematopoietic system: advances and questions","volume":"138","author":"Medvinsky","year":"2011","journal-title":"Development"},{"issue":"22","key":"10.1016\/bs.ircmb.2021.07.002_bb0180","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.002_bb0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.beha.2005.07.008","article-title":"Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options","volume":"19","author":"Mesa","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","article-title":"Phase1\/\u22122 study of pomalidomide in myelofibrosis","volume":"85","author":"Mesa","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0200","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.4081\/hr.2015.5714","article-title":"Pulmonary extramedullary hematopoiesis involving the pulmonary artery","volume":"7","author":"Monga","year":"2015","journal-title":"Hematol. Rep."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.06.2011.4392","article-title":"Pulmonary extramedullary haematopoiesis","volume":"2011","author":"Mubarak","year":"2011","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0215","first-page":"121","article-title":"Myelofibrosis: clinicopathologic features, prognosis, and management","volume":"16","author":"O'Sullivan","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0220","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.002_bb0225","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.leu.2402596","article-title":"Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study","volume":"16","author":"Piccaluga","year":"2002","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0230","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","article-title":"Haematopoietic stem cell activity and interactions with the niche","volume":"20","author":"Pinho","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-57-1-73","article-title":"A clinical and pathological study of seventy cases of myelofibrosis","volume":"57","author":"Pitcock","year":"1962","journal-title":"Ann. Intern. Med."},{"issue":"28","key":"10.1016\/bs.ircmb.2021.07.002_bb0240","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0245","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.stemcr.2018.04.003","article-title":"CXCL12\/CXCR4 signaling enhances human PSC-derived hematopoietic progenitor function and overcomes early in vivo transplantation failure","volume":"10","author":"Reid","year":"2018","journal-title":"Stem Cell Rep."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0250","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.critrevonc.2015.11.004","article-title":"Myeloproliferative neoplasms: current molecular biology and genetics","volume":"98","author":"Saeidi","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.002_bb0260","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1080\/10428194.2017.1312377","article-title":"Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome","volume":"58","author":"Shanmuganathan","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.002_bb0265","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/1097-0142(19860215)57:4<718::AID-CNCR2820570406>3.0.CO;2-P","article-title":"Treatment of polycythemia vera with hydroxyurea","volume":"57","author":"Sharon","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0270","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/2045893217702064","article-title":"Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series","volume":"7","author":"Singh","year":"2017","journal-title":"Pulm Circ."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0275","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1754-9485.2012.02397.x","article-title":"Extra-medullary haematopoiesis: a pictorial review of its typical and atypical locations","volume":"56","author":"Sohawon","year":"2012","journal-title":"J. Med. Imaging Radiat. Oncol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.002_bb0280","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/bs.ircmb.2021.07.002_bb0285","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0290","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.410050515","article-title":"Progressive myelopathy due to extramedullary hematopoiesis: case report and review of the literature","volume":"5","author":"Stahl","year":"1979","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.002_bb0295","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.002_bb0300","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"issue":"17","key":"10.1016\/bs.ircmb.2021.07.002_bb0305","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.002_bb0310","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V96.12.4007","article-title":"Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia","volume":"96","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0315","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International working group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.002_bb0320","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"27","key":"10.1016\/bs.ircmb.2021.07.002_bb0325","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.002_bb0330","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.002_bb0335","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":"Thalidomide therapy for myelofibrosis with myeloid metaplasia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.002_bb0340","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.002_bb0345","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.002_bb0350","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/leu.2015.310","article-title":"Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis","volume":"30","author":"Verstovsek","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.002_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.07.002_bb0360","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.leukres.2014.08.006","article-title":"Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis","volume":"38","author":"Wang","year":"2014","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.002_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.10075","article-title":"Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement","volume":"69","author":"Weinschenker","year":"2002","journal-title":"Am. J. Hematol."},{"issue":"14","key":"10.1016\/bs.ircmb.2021.07.002_bb0370","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00018-020-03450-w","article-title":"The mechanisms of pathological extramedullary hematopoiesis in diseases","volume":"77","author":"Yang","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0375","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720932038","article-title":"Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis","volume":"11","author":"Yoon","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/bs.ircmb.2021.07.002_bb0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2016.11.016","article-title":"Splenic irradiation for splenomegaly: a systematic review","volume":"53","author":"Zaorsky","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.07.002_bb0385","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/codi.13427","article-title":"A systematic review of presacral extramedullary haematopoiesis: a diagnosis to be considered for presacral masses","volume":"18","author":"Zhou","year":"2016","journal-title":"Colorectal Dis."}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:09:46Z","timestamp":1753787386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323899390"],"references-count":76,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.07.002","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}